CD8A and neoplasm: The cetuximab + pembrolizumab combination increased the ratio of human:mouse immune infiltration into the tumor, with no significant changes in the peripheral lymph organs, whereas ALX90, alone or in triple combination, increased proportions of the human CD8+ T cells only in the tumors (Fig. 1B; Supplementary Fig. S2A).